Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: A randomized EORTC-40013-22012/FFCD- 9203/GERCOR phase II study

Journal of Clinical Oncology

Volumn 28, Issue 29, 2010, Pages 4450-4456

  Van Laethem, Jean Luc ^a   Hammel, Pascal ^a   Mornex, Françoise ^a   Azria, David ^a   Van Tienhoven, Geertjan ^a   Vergauwe, Philippe ^a   Peeters, Marc ^a   Polus, Marc ^a   Praet, Michel ^a   Mauer, Murielle ^a   Collette, Laurence ^a   Budach, Volker ^a   Lutz, Manfred ^a   Van Cutsem, Eric ^a   Haustermans, Karin ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; DISEASE FREE SURVIVAL; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DIARRHEA; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEASIBILITY STUDIES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NAUSEA; PANCREATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; TREATMENT OUTCOME;

EID: 78049434513     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.30.3446     Document Type: Article

References (29)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics 2006. CA Cancer J Clin 56:106-130, 2006
2. Schnelldorfer T, Ware AL, Sarr MG, et al: Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: Is cure possible? Ann Surg 247:456-462, 2008
3. Kayahara M, Nagakawa T, Ueno K, et al: An evaluation of radical resection for pancreatic cancer based on the mode of recurrence as determined by autopsy and diagnostic imaging. Cancer 72:2118-2123, 1993 (Pubitemid 23280135)
4. Sener SF, Fremgen A, Menck HR, et al: Pancreatic cancer: A report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg 189:1-7, 1999
5. Kalser MH, Ellenberg SS: Pancreatic cancer: Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 120:899-903, 1985 (Pubitemid 15040883)
6. Corsini MM, Miller RC, Haddock MG, et al: Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: The Mayo clinic experience (1975-2005). J Clin Oncol 26:3511-3516, 2008
7. Herman JM, Swartz MJ, Hsu CC, et al: Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: Results of a large, prospectively collected database at the John Hopkins Hospital. J Clin Oncol 26:3503-3510, 2008
8. Neoptolemos JP, Stocken DD, Friess H, et al: A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350:1200-1210, 2004 (Pubitemid 38339364)
9. Oettle H, Post S, Neuhaus P, et al: Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial. JAMA 297:267-277, 2007 (Pubitemid 46143304)
10. Neuhaus P, Riess H, Post S, et al: CONKO- 001: Final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer (PC). J Clin Oncol 26:214s, 2008 (suppl; abstr LBA4504)
11. Smeenk HG, van Eijck CH, Hop WC, et al: Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: Long-term results of EORTC trial 40891. Ann Surg 246:734-740, 2007 (Pubitemid 350035648)
12. Neoptolemos J, Büchler M, Stocken DD, et al: ESPAC-3(v2): A multicenter, international, openlabel, randomized controlled phase III trial of adjuvant 5-fluorouracil/folinic acid (5-FU/FA) versus gemcitabine (GEM) in patients with resected pancreatic ductal adenocarcinoma. J Clin Oncol 27: 203s, 2009 (suppl; abstr LBA4505)
13. Burris HA 3rd, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 15:2403-2413, 1997 (Pubitemid 27251144)
14. Lawrence TS, Chang EY, Hahn TM, et al: Radiosensitization of pancreatic cancer cells by 2′,2′-difluoro-2′-deoxycytidine. Int J Radiat Oncol Biol Phys 34:867-872, 1996
15. Milas L, Fujii T, Hunter N, et al: Enhancement of tumor radioresponse in vivo by gemcitabine. Cancer Res 59:107-114, 1999 (Pubitemid 29062965)
16. Mason KA, Milas L, Hunter NR, et al: Maximizing therapeutic gain with gemcitabine and fractionated radiation. Int J Radiat Oncol Biol Phys 44:1125-1135, 1999 (Pubitemid 29342915)
17. Blackstock AW, Bernard SA, and Richards F, et al: Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. J Clin Oncol 17:2208-2212, 1999 (Pubitemid 29318854)
18. Murphy JD, Adusumilli S, Griffith KA, et al: Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 68:801-808, 2007 (Pubitemid 46818734)
19. Evans DB, Varadhachary GR, Crane CH, et al: Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 26:3496-3502, 2008
20. Van Laethem JL, Demols A, Gay F, et al: Postoperative adjuvant gemcitabine and concurrent radiation after curative resection of pancreatic head carcinoma: A phase II study. Int J Radiat Oncol Biol Phys 56:974-980, 2003 (Pubitemid 36794028)
21. Demols A, Peeters M, Polus M, et al: Adjuvant gemcitabine and concurrent continuous radiation (45 Gy) for resected pancreatic head carcinoma: A multicenter Belgian Phase II study. Int J Radiat Oncol Biol Phys 62:1351-1356, 2005 (Pubitemid 40982054)
22. Bryant J, Day R: Incorporating toxicity considerations into the design of two-stage phase II clinical trials. Biometrics 51:1372-1383, 1995 (Pubitemid 26030182)
23. Huguet F, André T, Hammel P, et al: Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 25:326-331, 2007 (Pubitemid 350003022)
24. Esposito I, Kleeff J, Bergmann F, et al: Most pancreatic cancer resections are R1 resections. Ann Surg Oncol 15:1651-1660, 2008
25. Chang DK, Johns AL, Merrett ND, et al: Margin clearance and outcome in resected pancreatic cancer. J Clin Oncol 27:2855-2862, 2009
26. Neoptolemos JP, Stocken DD, Dunn JA, et al: Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg 234:758-768, 2001 (Pubitemid 33117196)
27. Farrell JJ, Elsaleh H, Garcia M, et al: Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology 136:187-195, 2009
28. Maréchal R, Mackey JR, Lai R, et al: Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma. Clin Cancer Res 15: 2913-2919, 2009
29. Iacobuzio-Donahue CA, Fu B, Yachida S, et al: DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol 27:1806-1813, 2009